Physician profile
Laura Smart
NPI 1467642801
$2,565.32
in general payments reported to CMS, 2019-2025
23 companies · $841 in 2025
The $841 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $192 · 2021: $238 · 2022: $228 · 2023: $136 · 2024: $641 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $378.07 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $377.75 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $305.04 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.70 | 2019-2021 | |
| Madrigal Pharmaceuticals | $178.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $176.91 | 2024-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $158.75 | 2022-2025 | Terlivaz |
| Olympus America INC. | $123.85 | 2021-2025 | Single Use Electrosurgical Knife Kd-655 |
| Novartis Pharmaceuticals Corporation | $110.15 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $87.33 | 2025 | Tremfya |
| Abbvie INC. | $85.39 | 2020-2025 | |
| Medtronic, INC. | $73.28 | 2021 | |
| Intercept Pharmaceuticals, INC. | $45.35 | 2020-2025 | |
| Orphalan INC | $41.87 | 2024-2025 | Cuvrior |
| Erbe USA INC | $40.00 | 2023 | Erbe Vio3, Erbe |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mauna Kea Technologies, INC. | $26.63 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.89 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $19.69 | 2025 | Iqirvo |
| Qol Medical, LLC | $17.50 | 2024 | Sucraid |
| Aimmune Therapeutics, INC. | $16.36 | 2025 | Vowst |
| Alnylam Pharmaceuticals INC. | $14.06 | 2025 | Givlaari |
| Daiichi Sankyo INC. | $13.87 | 2019 | |
| Pfizer INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.